AdvaMed 2014 is the annual convening point for the medical device and diagnostics industry — where regulators, clinicians, investors and engineers meet to translate breakthrough science into therapies that reach patients faster, safer, and at scale.
AdvaMed 2014 grew out of a simple observation: the medical technology sector — one of the most heavily regulated, deeply technical, and globally consequential industries in the world — needed a single, neutral forum where the entire value chain could convene without commercial pretense. What began in the late 1990s as a Washington policy summit has matured into the premier business and innovation conference for medical devices, diagnostics, and digital health.
For more than fifteen years, AdvaMed's flagship conference has served as the place where FDA reviewers, hospital procurement leaders, startup founders, and chief executives hash out the questions that don't fit into any one company's roadmap: how do we design clinical trials that regulators can actually act on? How does reimbursement shape — and sometimes distort — innovation? And what does responsible AI look like when the data is generated by a patient's body?
The medtech community operates at the intersection of biology, engineering, and policy. Our job is to keep that intersection honest, productive, and focused on the patient.
Every panel, every exhibit, every networking conversation is anchored to one question: does this ultimately shorten the path between a clinical insight and the person whose life depends on it? Sessions that lose that thread are reframed or removed.
Innovation stalls where disciplines stop talking. We deliberately mix engineers with hospital systems, regulators with venture capital, payers with patient advocates — and we set ground rules that make honest disagreement more valuable than polite agreement.
Medical technology is a field where the cost of being wrong is measured in lives. Our program prioritizes peer-reviewed data, post-market evidence, and real-world outcomes over glossy launch narratives — and we expect every speaker to bring receipts.
Each year refines the conversation. Here's how the program has evolved alongside the industry it serves.
Held on Capitol Hill, the inaugural gathering brought together 40 medical device executives to discuss FDA reform and Medicare coverage policy.
Programming broadened to include international regulatory alignment, supply chain, and emerging markets — reflecting the globalization of medtech manufacturing.
Mobile medical apps, wireless patient monitoring, and connected devices were given their own stage, two years before FDA's final mHealth guidance.
AdvaMed 2014 centers on value-based care, post-market surveillance, cybersecurity for connected devices, and the regulatory path for combination products.
A snapshot of who shows up, what they bring, and the deals, partnerships, and policy shifts that move forward inside the conference walls.
A volunteer committee of senior medtech executives, clinicians, and policy specialists shapes every track. They recuse themselves from any session where their employer has a commercial interest.
Chief Medical Officer, Northbridge MedTech. Twenty years in cardiovascular device development; former FDA advisory committee member.
Partner, Halberd Health Strategies. Former Associate Director at CDRH; advises sponsors on de novo and breakthrough device pathways.
VP of Clinical Affairs at Quantiv Diagnostics. Leads the connected devices, SaMD, and AI/ML-enabled medical device programming.
Orthopedic surgeon and health economics researcher at Pacific Medical Center. Curates sessions on reimbursement, real-world evidence, and hospital purchasing.
Early registration for AdvaMed 2014 is now open. Securing your seat in advance also gives you priority access to the partner matching program and the Tuesday evening networking reception.
Reserve Your Seat